Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 16, 2023

SELL
$4.3 - $8.27 $41,585 - $79,979
-9,671 Reduced 14.13%
58,795 $261,000
Q4 2022

Feb 14, 2023

BUY
$5.66 - $8.42 $387,517 - $576,483
68,466 New
68,466 $576,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $89.8M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Susquehanna Fundamental Investments, LLC Portfolio

Follow Susquehanna Fundamental Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.